arrow
D

David F. McDermott

Dana-Farber Cancer Institute
H指数:109
被引数:8.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

高级泌尿肿瘤共识会议(AUC3)2025:肾细胞癌和尿路肿瘤管理的专家共识

2025-12-130
OAAI
Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma
2025-11-010
PRE
CD163+Tumor-Associated macrophages and clinical outcomes to First-Line nivolumab therapy in patients with metastatic clear cel renal cell carcinoma: insights from the HCRN GU16-260 trial

CD163+肿瘤相关巨噬细胞与转移性透明细胞肾细胞癌患者接受一线纳武利尤单抗治疗的临床结局:来自HCRN GU16-260试验的见解

2025-10-010
OAAI
Characterizing carbonic anhydrase 9 and HIF-2α RNA expression in clear cell renal cell carcinoma (ccRCC)

表征碳酸酐酶9和HIF-2α RNA在透明细胞肾细胞癌(ccRCC)中的表达

2025-10-010
OAAI
Immunotherapy response correlates in metastatic clear cell renal cell carcinoma from circulating cell-free epigenomes

转移性透明细胞肾细胞癌中循环游离表观基因组与免疫治疗效果的关联

2025-10-010
OAAI
Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes
2025-02-010
PRE
Nivolumab plus ipilimumab versus sunitinib for fi rst-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Nivolumab联合ipilimumab与舒尼替尼用于晚期肾细胞癌的一线治疗: CheckMate 214 III期试验的疗效和安全性的8年随访结果

2024-11-010
OAAI
Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)

卡博替尼(Cabo)联合纳武利尤单抗(Nivo)和伊匹木单抗(Ipi)治疗不同组织学类型的晚期肾细胞癌(RCCdh)的II期研究更新结果

2024-09-010
PRE
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma

肺免疫预后指数 (LIPI) 作为转移性肾细胞癌预后生物标志物的验证

2024-06-013
PRE
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

辅助Pembrolizumab治疗肾细胞癌的总生存率

2024-04-1840
PRE
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

nivolumab和savage nivolumab/ipilimumab治疗晚期透明细胞肾细胞癌的II期研究的无治疗生存结果 (HCRN GU16-260-Cohort A)

2024-04-112
OAAI
Initial results from a phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132)
2024-04-051
PRE
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
2024-03-0112
OAAI
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort

Beztifan治疗晚期实体瘤的I期LITESPARK-001研究: 在透明细胞肾细胞癌队列中延长41个月的随访

2024-01-017
PRE